MMV is a not-for-profit organization created in 1999 to discover, develop and deliver new,...
FAQs
As with most other PDPs, MMV’s R&D activities are not conducted on our own premises. Instead...
Yes. The ‘virtual’ R&D portfolio managed by MMV is efficient, cost effective and in a number...
Cost-effectiveness can only be judged retrospectively, once MMV has registered a new drug and...
‘In-kind’ contributions include the use of facilities, pharmaceutical technologies such as high-...
No. MMV was founded following discussions between several organizations, including the WHO....
MMV recognizes that the pharmaceutical industry is the keeper of all knowledge and expertise...
When MMV enters into contractual relationships with its partners, its primary goal is to ensure...
Building research capacity in disease-endemic countries is not a core MMV activity. However, it...
MMV has received funding from a number of philanthropic, public and private sector and...
MMV has a regularly updated ‘business plan’ and dynamic budget process that constantly models...
MMV publishes its audited financial statements in full in its Annual Report every year. This...
Several organizations are involved in the fight to defeat malaria. In part this is because it is...
MMV does not provide grants for projects, but usually has an annual call for proposals during...
Except for some products such as treatment for severe malaria, nearly all of the antimalarial...
In agreement with its pharmaceutical partners, MMV has several miniportfolios within its...
Drug development is invariably risky. In developing these different artemisinin combination...
MMV believes strongly that in order to develop quality products, our work must also be of the...
MMV’s strong commitment to quality is in line with our regulatory strategy. We aim to have all...
While our initial objectives to accelerate the registration of our late-stage products and...
As ACTs begin to be widely used in malaria-endemic countries, the public health community is...
MMV’s Expert Scientific Advisory Committee (ESAC) helps to identify the best projects worthy of...
When MMV was established in 1999 as a not-for-profit PDP, its mission was to discover, develop...
Although between 200–600 antimalarial drugs are available in Africa, the effective drugs are not...
Success for MMV means that its new drugs, once developed and registered by an international drug...
Sustainable health impact implies a reduction in the malaria burden in disease-endemic countries...
Due to the huge gaps in the current ACT distribution system, improving access to more effective...
Communication and advocacy is a key part of the MMV access strategy. MMV has taken an active...
Since 2005, the MMV access team has grown. An Access and Delivery Advisory Committee (ADAC) with...
Mirroring the ‘virtual R&D’ model, MMV’s access exemplifies ‘virtual delivery’. MMV is not...
MMV’s focus on the needs of endemic countries gives rise to the need for strong input and advice...
Following in the footsteps of Coartem® Dispersible we have two more ACTs...
AIDS, TB and malaria are the by far the world’s worst communicable diseases, each causing...
Antimalarial drugs have been one of humanity’s most precious and cost-effective public health...
Defeating malaria requires a comprehensive approach. There is no magic bullet. Insecticide...
Killing the mosquitoes that transmit malaria – vector control – is an established method for...
MMV and its partners work on a not-for-profit basis to research and develop effective anti-...
